OWP
SRNE

Obermeyer Wealth Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Obermeyer Wealth Partners’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,000
Closed -$63K – 154
2020
Q2 		$63K Hold
10,000
– – 0.01% 135
2020
Q1 		$18K Hold
10,000
– – ﹤0.01% 118
2019
Q4 		$34K Buy
+10,000
New +$23.8K ﹤0.01% 133

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Obermeyer Wealth Partners's SRNE Position: Q3 2020 in Review

Obermeyer Wealth Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2020, closing a stake of 10,000 shares — an estimated $63K sold.

Obermeyer Wealth Partners first reported a position in SRNE in Q4 2019 and held it in 3 quarters. The position peaked at $63K in Q2 2020. 209 funds tracked by Wall St. Rank hold SRNE as of Q3 2020.

  • Obermeyer Wealth Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2020 after selling out during the quarter.
  • Obermeyer Wealth Partners sold 10,000 Sorrento Therapeutics, Inc. shares in Q3 2020, an estimated $63K.
  • Obermeyer Wealth Partners first reported a position in Sorrento Therapeutics, Inc. in Q4 2019 and held it in 3 quarters.
  • Obermeyer Wealth Partners's Sorrento Therapeutics, Inc. position peaked at $63K in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2020.

Based on Obermeyer Wealth Partners's 13F filing for Q3 2020, filed 22 Oct 2020.